EFTA01446853.txt Text dataset_10 View on DOJ

Illegal Activity
none
Blackmail
none
Date
2014-2015
Document Type
email
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41
Summary
This email from EVS Equity on behalf of Deutsche Bank provides an analysis of Gilead's tax rate and valuation, projecting a 2015 EPS of $7.75/sh and valuing GILD at $5132/sh. The analysis considers the impact of Sovaldi sales and generic Sustiva on Gilead's financial performance.
Metadata
Subject
Gilead (GILD) Tax Rate Analysis and Valuation
Sender
EVS Equity
Recipients
Document ID
DB-SDNY-0101259, SDNY_GM_00247443
Date
2014-2015
Relationships 3
Entity 1RelationshipEntity 2Description
Gilead (GILD) Financial Analysis Deutsche Bank Deutsche Bank provides equity research and valuation of Gilead.
Evalueserve Service Provider Deutsche Bank Evalueserve sends the email on behalf of Deutsche Bank.
Tazia Smith Employment Deutsche Bank Securities Inc Tazia Smith is a Director at Deutsche Bank Securities Inc.
Notable Quotes 2
Gilead still remains our top pick in large cap
we value GILD at 5132/sh using 17x 2015 multiple (10% discount to its biotech peers due to patent cliff on base biz). our new '15 EPS is 57.75/sh.
Financial Information
Amounts:5132/sh57.75/sh10c
Assets:
  • Gilead (GILD) stock
  • Sovaldi sales
  • Sustiva royalty payments
Transactions:
  • Tax rate analysis for Gilead (GILD)
  • Valuation of GILD at 5132/sh using 17x 2015 multiple
  • Estimation of '14 tax rate at 23% decreasing to 18% over time if sovaldi hits revenue estimate
  • Calculation of 2014 tax rate at -23.5%
  • Implied sovaldi tax rate at -13%
  • Weighted avg. tax rate for 2015 at -21%
Public Knowledge
Context
Financial analysis of a publicly traded company is often of interest to the media.
Media Worthy
Yes
Raw Analysis JSON click to expand
Themes
Financial transactions/money flowBusiness dealings
Organizations 5
Gilead (GILD)Deutsche BankEvalueserveDeutsche Bank Securities IncDeutsche Asset & wealth Management
Locations 4
EuropeUSNew York, NY345 Park Avenue, 26th Floor, New York, NY 10154
Financial Entities 1
Deutsche Bank
Text Analysis
Tone
Professional
Purpose
To provide an analysis of Gilead's tax rate and valuation, including the impact of Sovaldi sales and generic Sustiva.
Significance
The document provides financial analysis and projections for Gilead, a large-cap biotech company, focusing on tax rates, revenue estimates, and valuation.
File Info
File Name
EFTA01446853.txt
Dataset
dataset_10
Type
Text
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41:07.850398
DOJ Source
View on DOJ